Literature DB >> 28679322

Prevalence and co-prevalence of comorbidities in Belgian patients with type 2 diabetes mellitus: a transversal, descriptive study.

Michel P Hermans1, Nicolas Dath2.   

Abstract

OBJECTIVES: Most patients with type 2 diabetes mellitus (T2DM) have at least one comorbid chronic disease. These comorbidities increase disease burden and costs and may impact the selection of glucose-lowering therapies. The aim of our study was to describe the prevalence and co-prevalence of comorbidities in patients with T2DM in Belgium.
METHODS: This was a single centre, transversal, descriptive study performed at Saint-Luc University Hospital, Brussels, Belgium. T2DM patients aged >18 years presenting to the outpatient diabetes clinic and regularly followed (≥1 year) between July 2011 and 2016 were included in the database. Information on descriptive characteristics was collected and several comorbidities were assessed.
RESULTS: Overall, 778 patients were included. The median age was 68 years. The most frequently observed comorbidities were hypertension (85.5%), metabolic syndrome (MetS; 84.6%) and non-alcoholic hepatic steatosis (71.7%). 78.5% of the T2DM patients had ≥4 comorbidities. The highest co-prevalence of comorbidities was the combination of MetS and hypertension (75.8%), MetS and overweight (60.5%), and hypertension and overweight (56.6%).
CONCLUSION: The observed prevalence and co-prevalence of comorbidities in T2DM Belgian patients was high, with 95.0% patients having at least two comorbid conditions.

Entities:  

Keywords:  Belgium; Type 2 diabetes mellitus; comorbidities; prevalence

Mesh:

Year:  2017        PMID: 28679322     DOI: 10.1080/17843286.2017.1348710

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  7 in total

Review 1.  Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes.

Authors:  René Rodríguez-Gutiérrez; Juan Manuel Millan-Alanis; Francisco J Barrera; Rozalina G McCoy
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

Review 2.  Bioactive Properties of Marine Phenolics.

Authors:  Raquel Mateos; José Ricardo Pérez-Correa; Herminia Domínguez
Journal:  Mar Drugs       Date:  2020-09-30       Impact factor: 5.118

3.  Validation of Two Automatic Blood Pressure Monitors With the Ability to Transfer Data via Bluetooth.

Authors:  Madeleine Wetterholm; Stephanie Erika Bonn; Christina Alexandrou; Marie Löf; Ylva Trolle Lagerros
Journal:  J Med Internet Res       Date:  2019-04-17       Impact factor: 5.428

4.  MorbiNet: multimorbidity networks in adult general population. Analysis of type 2 diabetes mellitus comorbidity.

Authors:  Alba Aguado; Ferran Moratalla-Navarro; Flora López-Simarro; Victor Moreno
Journal:  Sci Rep       Date:  2020-02-12       Impact factor: 4.379

5.  Scale-up integrated care for diabetes and hypertension in Cambodia, Slovenia and Belgium (SCUBY): a study design for a quasi-experimental multiple case study.

Authors:  Josefien van Olmen; Sonia Menon; Antonija Poplas Susič; Por Ir; Kerstin Klipstein-Grobusch; Edwin Wouters; José L Peñalvo; Črt Zavrnik; Vannarath Te; Monika Martens; Katrien Danhieux; Savina Chham; Natasa Stojnić; Veerle Buffel; Sokunthea Yem; Gareth White; Daniel Boateng; Zalika Klemenc-Ketis; Valentina Rupel Prevolnik; Roy Remmen; Wim Van Damme
Journal:  Glob Health Action       Date:  2020-12-31       Impact factor: 2.640

6.  Prevalence of comorbidities and their associated factors in patients with type 2 diabetes at a tertiary care department in Ningbo, China: a cross-sectional study.

Authors:  Xueyu Li; Kaushik Chattopadhyay; Shengnan Xu; Yanshu Chen; Miao Xu; Li Li; Jialin Li
Journal:  BMJ Open       Date:  2021-01-07       Impact factor: 2.692

7.  Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population-based cross-sectional study.

Authors:  Manel Mata-Cases; Josep Franch-Nadal; Jordi Real; Marta Cedenilla; Didac Mauricio
Journal:  BMJ Open       Date:  2019-10-28       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.